Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Tokyo Big Sight

11 nov 2018 9:30 a.m. - 13 nov 2018 5:40 p.m.

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

15th DIA Japan Annual Meeting 2018

Innovative technologies such as AI, big data/genomics, and cell/gene therapies are poised to transform healthcare product development across the globe – join us to discuss these topics.

[V4-S4] It’s Time to Think About Compliance to Deliver Value Added Medical Information - Current and Ideal Situation of Medical Iformation Provision

Session Chair(s)

D. Stuart  Sowder, JD, PharmD, MBA

D. Stuart Sowder, JD, PharmD, MBA

Vice President, Compliance Lead, Asia, Pacific, Africa, Middle East

Pfizer Holdings, United States

Following the daily changing scientific and ethical approach, data building that collected our wisdom will be the basis of application for approval. How should we provide the approved data to health care professionals and contribute to the improvement of medical quality? The advertisement activity surveillance monitor system began and entered the second year. It seems that the time has come when we must consider for our actions and ethical standards together with our stakeholders instead of considering the compliance by a single organization. In this session, we are going to discuss the current or future direction in Japan following global trend regarding medical information provision with compliance experts from each pharmaceutical association (JPMA, PhRMA, EFPIA), academia and regulatory authority.

Speaker(s)

Yasuyuki  Katayama, MD, PhD

It’s Time to Think About Compliance to Deliver Value Added Medical Information -Current and Ideal Situation of Medical Information Provision-

Yasuyuki Katayama, MD, PhD

Pfizer Japan Inc., Japan

Corporate Officer, Country Medical Director and Head of Medical Japan

Tokuo  Tanaka

Initiatives Toward Appropriate Advertisement Activities in JPMA

Tokuo Tanaka

Japan Pharmaceutical Manufacturers Association (JPMA), Japan

Managing Director

Makoto  Shiragami, PhD

Problems of Drug Promotion Activities Emerging from Report from Advertisement Surveillance Monitoring

Makoto Shiragami, PhD

Teikyo Heisei University, Japan

Professor, Faculty of Pharmaceutical Sciences

Takamasa  Horio, JD

Guidelines on Pharmaceutical Product Communications

Takamasa Horio, JD

Ministry of Health, Labour and Welfare (MHLW), Japan

Legal Advisor, Compliance and Narcotics Division

Kunio  Kawajiri

Kunio Kawajiri

Astellas Pharma Inc., Japan

Healthcare Compliance Group, Ethics & Compliance Department

Kana  Matsumura

Kana Matsumura

Sanofi K.K., Japan

Legal Counsel, Legal

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.